Medicine
Nipride Rtu 20 mg/100 mL injection
Nipride Rtu 20 mg/100 mL injection is a prescription medicine containing Sodium nitroprusside for intravenous use, marketed by Exela Pharma Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F). To protect NIPRIDE ® RTU from light, vial…
Key facts
- Active ingredient (INN)
- Sodium nitroprusside
- Brand
- Nipride Rtu
- Strength
- 20 mg/100 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 100 mL
- Marketing authorisation holder
- Exela Pharma Sciences
- Manufacturer
- Exela Pharma Sciences
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F). To protect NIPRIDE ® RTU from light, vial should be stored in its carton until used.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 July 2018
- Identifiers
- RxCUI 1876368, 1876373, 1999185 +3DailyMed set ID 5acf0836-93ff-4064-b888-3f560e8a558dNDC 51754-1029Application NDA209387
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 100 mL in 1 vial | 51754-1029-1 | Exela Pharma Sciences | 20 July 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 May 1974 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Sodium nitroprusside 20 mg/100 mL injection.
Other strengths and forms of Sodium nitroprusside
Clinical summary
Sodium nitroprusside is a vasodilator indicated for immediate reduction of blood pressure, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Sodium nitroprusside for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Sodium nitroprussideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NIPRIDE RTU prescribing information (Exela Pharma Sciences) · U.S. National Library of Medicine, DailyMed
Need Nipride Rtu 20 mg/100 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.